Trials / Completed
CompletedNCT06577428
A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes
Effect of Injection Site on the Relative Bioavailability of a Single Dose of RAY1225 in Subjects With Low and High Body Mass Index
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the amount of RAY1225 that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of RAY1225 will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 7 weeks, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAY1225 | administered SC |
Timeline
- Start date
- 2024-07-30
- Primary completion
- 2024-09-29
- Completion
- 2024-10-08
- First posted
- 2024-08-29
- Last updated
- 2025-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06577428. Inclusion in this directory is not an endorsement.